Using prostate cancer as an exemplar, we showed that acquisition of pluripotent master regulators drove castration resistance independent from conventional AR related signalling and uncovered the TH pathway as a new treatment target for castration-resistant disease. This evidence concerns the gene TH and Familial prostate cancer.